JNJ

190.4

-1.08%↓

ABT

127.34

-0.46%↓

MDT

93.89

+0.11%↑

VEEV

294.61

+2.1%↑

A

147.77

+1.08%↑

JNJ

190.4

-1.08%↓

ABT

127.34

-0.46%↓

MDT

93.89

+0.11%↑

VEEV

294.61

+2.1%↑

A

147.77

+1.08%↑

JNJ

190.4

-1.08%↓

ABT

127.34

-0.46%↓

MDT

93.89

+0.11%↑

VEEV

294.61

+2.1%↑

A

147.77

+1.08%↑

JNJ

190.4

-1.08%↓

ABT

127.34

-0.46%↓

MDT

93.89

+0.11%↑

VEEV

294.61

+2.1%↑

A

147.77

+1.08%↑

JNJ

190.4

-1.08%↓

ABT

127.34

-0.46%↓

MDT

93.89

+0.11%↑

VEEV

294.61

+2.1%↑

A

147.77

+1.08%↑

Search

Beam Therapeutics Inc

Open

SectorGezondheidszorg

28.12 1.37

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

27.65

Max

28.65

Belangrijke statistieken

By Trading Economics

Inkomsten

7M

-102M

Verkoop

996K

8.5M

Winstmarge

-1,208.257

Werknemers

509

EBITDA

17M

-97M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+52.46% upside

Dividenden

By Dow Jones

Volgende Winsten

4 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.2B

3.1B

Vorige openingsprijs

26.75

Vorige sluitingsprijs

28.12

Nieuwssentiment

By Acuity

47%

53%

157 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Beam Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 okt 2025, 20:49 UTC

Winsten

Correction to Thermo Fisher Article on Oct. 22

23 okt 2025, 23:51 UTC

Marktinformatie

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 okt 2025, 23:49 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

23 okt 2025, 23:49 UTC

Marktinformatie

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 okt 2025, 23:37 UTC

Marktinformatie

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 okt 2025, 22:58 UTC

Marktinformatie

Global Energy Roundup: Market Talk

23 okt 2025, 22:57 UTC

Marktinformatie

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 okt 2025, 22:49 UTC

Acquisities, Fusies, Overnames

How Trump Sparked a New Era of State Capitalism -2-

23 okt 2025, 22:49 UTC

Acquisities, Fusies, Overnames

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 okt 2025, 22:17 UTC

Winsten

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 okt 2025, 21:41 UTC

Winsten

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 okt 2025, 21:05 UTC

Winsten

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 okt 2025, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

23 okt 2025, 20:50 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

23 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

23 okt 2025, 20:35 UTC

Winsten

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 okt 2025, 20:28 UTC

Winsten

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 okt 2025, 20:15 UTC

Marktinformatie
Winsten

Global Commodities Roundup: Market Talk

23 okt 2025, 20:10 UTC

Winsten

Newmont Mining 3Q Adj EPS $1.71

23 okt 2025, 20:10 UTC

Winsten

Newmont Mining 3Q Sales $5.52B

23 okt 2025, 20:10 UTC

Winsten

Newmont Mining 3Q EPS $1.67

23 okt 2025, 20:09 UTC

Winsten

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 okt 2025, 20:07 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

23 okt 2025, 20:07 UTC

Marktinformatie
Winsten

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 okt 2025, 20:07 UTC

Winsten

Blackstone Looks to IPOs for Investment Exits -- Update

23 okt 2025, 20:05 UTC

Winsten

Intel 3Q Gross Margin 38.2% >INTC

23 okt 2025, 20:04 UTC

Winsten

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 okt 2025, 20:04 UTC

Winsten

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 okt 2025, 20:04 UTC

Winsten

Intel: 4Q Guidance Excludes Altera >INTC

23 okt 2025, 20:04 UTC

Winsten

Intel Sees 4Q Adj EPS 8c >INTC

Peer Vergelijking

Prijswijziging

Beam Therapeutics Inc Prognose

Koersdoel

By TipRanks

52.46% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 42.2 USD  52.46%

Hoogste 80 USD

Laagste 20 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Beam Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

11

Buy

2

Hold

0

Sell

Technische score

By Trading Central

16.225 / 20.17Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Very Strong Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

157 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
help-icon Live chat